柚皮苷抗骨质疏松作用机制解析：网络药理学与孟德尔随机化研究
Naringin’s Anti-Osteoporosis Mechanisms Unveiled: A Network Pharmacology and Mendelian Randomization
DOI: 10.12677/pi.2026.152015, PDF,    国家自然科学基金支持
作者: 齐 新：黑龙江中医药大学附属第二临床医学院，黑龙江 哈尔滨；李小冬, 徐西林*：黑龙江中医药大学附属第三医院骨科，黑龙江 哈尔滨
关键词: 骨质疏松症；柚皮苷；网络药理学；孟德尔随机化；分子对接；Osteoporosis； Naringin； Network Pharmacology； Mendelian Randomization； Molecular Docking
摘要: 目的：本研究旨在通过网络药理学、孟德尔随机化及分子对接技术，验证柚皮苷的抗骨质疏松作用。方法：利用Cytoscape软件与R语言，构建“柚皮苷–靶基因–GO及KEGG–骨质疏松症”分析框架。整合公共数据库资源，开展蛋白质–蛋白质相互作用(PPI)、基因本体(GO)及京都基因与基因组百科全书(KEGG)等分析。结果：筛选出柚皮苷相关靶基因272个、骨质疏松症相关靶基因5785个，获得交集靶基因197个。核心靶基因包括TP53、TNF、JUN、STAT3、AKT1、ESR1、BCL2及IL6。另外GAL、TNFSF11及SPP1被鉴定为影响骨质疏松症的可成药蛋白，同时也是柚皮苷的潜在作用靶点。功能富集分析显示，柚皮苷可能通过调控细胞凋亡、细胞增殖及炎症反应，以及TNF、FoxO、PI3K-Akt等信号通路发挥抗骨质疏松作用。分子对接结果表明，柚皮苷与上述靶点具有较高的结合亲和力。结论：柚皮苷的抗骨质疏松治疗机制可能涉及调控基因表达及介导信号通路，进而影响成骨细胞增殖、凋亡、血管生成及炎症反应。
Abstract: Objective: This study aimed to validate its effects using network pharmacology, Mendelian randomization, and molecular docking. Methods: We constructed a “Naringin-Targets-GO and KEGG-Osteoporosis” analysis framework with Cytoscape and R, integrating public databases and analyses including PPI, GO, and KEGG. Results: We identified 272 naringin-related and 5,785 osteoporosis-related target genes, with 197 overlaps. Core targets include TP53, TNF, JUN, STAT3, AKT1, ESR1, BCL2, and IL6. Additionally, GAL, TNFSF11, and SPP1 were identified as druggable proteins affecting osteoporosis and potential targets for naringin. Functional enrichment analyses indicated naringin might regulate osteoporosis by influencing apoptosis, cell proliferation, and inflammation, as well as TNF, FoxO, and PI3K-Akt pathways. Molecular docking showed high binding affinity of naringin to these targets. Conclusion: Naringin’s therapeutic mechanism may involve gene regulation and mediation of signaling pathways, affecting osteoblast proliferation, apoptosis, angiogenesis, and inflammation.
文章引用：齐新, 李小冬, 徐西林. 柚皮苷抗骨质疏松作用机制解析：网络药理学与孟德尔随机化研究[J]. 药物资讯, 2026, 15(2): 123-138. https://doi.org/10.12677/pi.2026.152015

参考文献

[1] Gregson, C.L., Armstrong, D.J., Bowden, J., Cooper, C., Edwards, J., Gittoes, N.J.L., Harvey, N., et al. (2022) UK Clinical Guideline for the Prevention and Treatment of Osteoporosis. Archives of Osteoporosis, 17, Article 58.
[2] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2022) [J]. 中国全科医学, 2023, 26(14): 1671-1691.
[3] Khosla, S. and Hofbauer, L.C. (2017) Osteoporosis Treatment: Recent Developments and Ongoing Challenges. The Lancet Diabetes & Endocrinology, 5, 898-907. [Google Scholar] [CrossRef] [PubMed]
[4] Adamczak, A., Ożarowski, M. and Karpiński, T.M. (2019) Antibacterial Activity of Some Flavonoids and Organic Acids Widely Distributed in Plants. Journal of Clinical Medicine, 9, Article 109. [Google Scholar] [CrossRef] [PubMed]
[5] Zhang, F., Huang, X., Qi, Y., Qian, Z., Ni, S., Zhong, Z., et al. (2021) Juglanin Inhibits Osteoclastogenesis in Ovariectomized Mice via the Suppression of NF-κB Signaling Pathways. Frontiers in Pharmacology, 11, Article ID: 596230. [Google Scholar] [CrossRef] [PubMed]
[6] Ge, X. and Zhou, G. (2021) Protective Effects of Naringin on Glucocorticoid-Induced Osteoporosis through Regulating the PI3K/AKT/mTOR Signaling Pathway. American Journal of Translational Research, 13, 6330-6341.
[7] Cao, X., Lin, W., Liang, C., Zhang, D., Yang, F., Zhang, Y., et al. (2015) Naringin Rescued the TNF-α-Induced Inhibition of Osteogenesis of Bone Marrow-Derived Mesenchymal Stem Cells by Depressing the Activation of NF-кB Signaling Pathway. Immunologic Research, 62, 357-367. [Google Scholar] [CrossRef] [PubMed]
[8] Ma, X., Lv, J., Sun, X., Ma, J., Xing, G., Wang, Y., et al. (2016) Naringin Ameliorates Bone Loss Induced by Sciatic Neurectomy and Increases Semaphorin 3A Expression in Denervated Bone. Scientific Reports, 6, Article No. 24562. [Google Scholar] [CrossRef] [PubMed]
[9] Cao, G., Hu, S., Ning, Y., Dou, X., Ding, C., Wang, L., et al. (2024) Traditional Chinese Medicine in Osteoporosis: From Pathogenesis to Potential Activity. Frontiers in Pharmacology, 15, Article ID: 1370900. [Google Scholar] [CrossRef] [PubMed]
[10] Wang, F., Rong, P., Wang, J., Yu, X., Wang, N., Wang, S., et al. (2022) Anti-Osteoporosis Effects and Regulatory Mechanism of Lindera aggregata Based on Network Pharmacology and Experimental Validation. Food & Function, 13, 6419-6432. [Google Scholar] [CrossRef] [PubMed]
[11] Finan, C., Gaulton, A., Kruger, F.A., Lumbers, R.T., Shah, T., Engmann, J., et al. (2017) The Druggable Genome and Support for Target Identification and Validation in Drug Development. Science Translational Medicine, 9, eaag1166. [Google Scholar] [CrossRef] [PubMed]
[12] Dönertaş, H.M., Fabian, D.K., Fuentealba, M., Partridge, L. and Thornton, J.M. (2021) Common Genetic Associations between Age-Related Diseases. Nature Aging, 1, 400-412. [Google Scholar] [CrossRef] [PubMed]
[13] Paquet, E. and L. Viktor, H. (2013) Macromolecular Structure Comparison and Docking: An Algorithmic Review. Current Pharmaceutical Design, 19, 2183-2193. [Google Scholar] [CrossRef] [PubMed]
[14] Gan, J., Deng, X., Le, Y., Lai, J. and Liao, X. (2023) The Development of Naringin for Use against Bone and Cartilage Disorders. Molecules, 28, Article 3716. [Google Scholar] [CrossRef] [PubMed]
[15] Lodewyckx, L. and Lories, R.J.U. (2009) WNT Signaling in Osteoarthritis and Osteoporosis: What Is the Biological Significance for the Clinician? Current Rheumatology Reports, 11, 23-30. [Google Scholar] [CrossRef] [PubMed]
[16] Jiang, Q., Li, W.Q., Aiello, F.B., Mazzucchelli, R., Asefa, B., Khaled, A.R., et al. (2005) Cell Biology of IL-7, a Key Lymphotrophin. Cytokine & Growth Factor Reviews, 16, 513-533. [Google Scholar] [CrossRef] [PubMed]
[17] 王文驰, 武瑞骐, 黄杰荣, 等. 柚皮苷防治骨质疏松症的分子机制[J]. 中国组织工程研究, 2024, 28(34): 5528-5535.
[18] Yu, X., Shen, G., Shang, Q., Zhang, Z., Zhao, W., Zhang, P., et al. (2021) A Naringin-Loaded Gelatin-Microsphere/Nano-Hydroxyapatite/Silk Fibroin Composite Scaffold Promoted Healing of Critical-Size Vertebral Defects in Ovariectomised Rat. International Journal of Biological Macromolecules, 193, 510-518. [Google Scholar] [CrossRef] [PubMed]
[19] McLean, R.R. (2009) Proinflammatory Cytokines and Osteoporosis. Current Osteoporosis Reports, 7, 134-139. [Google Scholar] [CrossRef] [PubMed]
[20] Ang, E.S.M., Yang, X., Chen, H., Liu, Q., Zheng, M.H. and Xu, J. (2011) Naringin Abrogates Osteoclastogenesis and Bone Resorption via the Inhibition of Rankl-Induced NF-κB and ERK Activation. FEBS Letters, 585, 2755-2762. [Google Scholar] [CrossRef] [PubMed]
[21] Tanaka, Y., Nakayamada, S. and Okada, Y. (2005) Osteoblasts and Osteoclasts in Bone Remodeling and Inflammation. Current Drug Target-Inflammation & Allergy, 4, 325-328. [Google Scholar] [CrossRef] [PubMed]
[22] Han, Y., Gao, H., Gan, X., Liu, J., Bao, C. and He, C. (2024) Roles of IL-11 in the Regulation of Bone Metabolism. Frontiers in Endocrinology, 14, Article ID: 1290130. [Google Scholar] [CrossRef] [PubMed]
[23] Fischer, V. and Haffner-Luntzer, M. (2022) Interaction between Bone and Immune Cells: Implications for Postmenopausal Osteoporosis. Seminars in Cell & Developmental Biology, 123, 14-21. [Google Scholar] [CrossRef] [PubMed]
[24] Jung, Y.Y., Kim, C., Shanmugam, M.K., Deivasigamani, A., Chinnathambi, A., Alharbi, S.A., et al. (2024) Leonurine Ameliorates the STAT3 Pathway through the Upregulation of SHP-1 to Retard the Growth of Hepatocellular Carcinoma Cells. Cellular Signalling, 114, Article 111003. [Google Scholar] [CrossRef] [PubMed]
[25] Wang, W., Mao, J., Chen, Y., Zuo, J., Chen, L., Li, Y., et al. (2022) Naringin Promotes Osteogenesis and Ameliorates Osteoporosis Development by Targeting JAK2/STAT3 Signalling. Clinical and Experimental Pharmacology and Physiology, 49, 113-121. [Google Scholar] [CrossRef] [PubMed]
[26] Rhee, J., Park, S., Kim, S., Kim, J., Ha, C., Chun, C., et al. (2017) Inhibition of BATF/JUN Transcriptional Activity Protects against Osteoarthritic Cartilage Destruction. Annals of the Rheumatic Diseases, 76, 427-434. [Google Scholar] [CrossRef] [PubMed]
[27] Di Cicco, G., Marzano, E., Mastrostefano, A., Pitocco, D., Castilho, R.S., Zambelli, R., et al. (2024) The Pathogenetic Role of RANK/RANKL/OPG Signaling in Osteoarthritis and Related Targeted Therapies. Biomedicines, 12, Article 2292. [Google Scholar] [CrossRef] [PubMed]
[28] Pavalko, F.M., Gerard, R.L., Ponik, S.M., Gallagher, P.J., Jin, Y. and Norvell, S.M. (2002) Fluid Shear Stress Inhibits TNF‐α‐Induced Apoptosis in Osteoblasts: A Role for Fluid Shear Stress‐induced Activation of PI3‐Kinase and Inhibition of Caspase‐3. Journal of Cellular Physiology, 194, 194-205. [Google Scholar] [CrossRef] [PubMed]
[29] Zhang, H., Zhou, C., Zhang, Z., Yao, S., Bian, Y., Fu, F., et al. (2022) Integration of Network Pharmacology and Experimental Validation to Explore the Pharmacological Mechanisms of Zhuanggu Busui Formula against Osteoporosis. Frontiers in Endocrinology, 12, Article ID: 841668. [Google Scholar] [CrossRef] [PubMed]
[30] Chokalingam, K., Roforth, M.M., Nicks, K.M., McGregor, U., Fraser, D., Khosla, S., et al. (2012) Examination of ERα Signaling Pathways in Bone of Mutant Mouse Models Reveals the Importance of ERE-Dependent Signaling. Endocrinology, 153, 5325-5333. [Google Scholar] [CrossRef] [PubMed]
[31] Nakamura, T., Imai, Y., Matsumoto, T., Sato, S., Takeuchi, K., Igarashi, K., et al. (2007) Estrogen Prevents Bone Loss via Estrogen Receptor Α and Induction of Fas Ligand in Osteoclasts. Cell, 130, 811-823. [Google Scholar] [CrossRef] [PubMed]
[32] Scheffler, J.M., Gustafsson, K.L., Barrett, A., Corciulo, C., Drevinge, C., Del Carpio Pons, A.M., et al. (2022) ERα Signaling in a Subset of CXCL12 ‐Abundant Reticular Cells Regulates Trabecular Bone in Mice. JBMR Plus, 6, e10657. [Google Scholar] [CrossRef] [PubMed]
[33] Fang, P., Yu, M., Guo, L., Bo, P., Zhang, Z. and Shi, M. (2012) Galanin and Its Receptors: A Novel Strategy for Appetite Control and Obesity Therapy. Peptides, 36, 331-339. [Google Scholar] [CrossRef] [PubMed]
[34] Wawrzyniak, A., Skrzypczak-Zielinska, M., Krela-Kazmierczak, I., Michalak, M., Marszalek, D., Marcinkowska, M., et al. (2020) Analysis of the Tumor Necrosis Factor Superfamily Member 11 Gene Polymorphism with Bone Mineral Density and Bone Fracture Frequency in Patients with Postmenopausal Osteoporosis. Advances in Medical Sciences, 65, 291-297. [Google Scholar] [CrossRef] [PubMed]
[35] Bae, S., Kim, K., Kang, K., Kim, H., Lee, M., Oh, B., et al. (2023) Rankl-Responsive Epigenetic Mechanism Reprograms Macrophages into Bone-Resorbing Osteoclasts. Cellular & Molecular Immunology, 20, 94-109. [Google Scholar] [CrossRef] [PubMed]
[36] Kulik-Rechberger, B. and Kozłowska, M. (2024) Osteoprotegerin and Receptor Activator of the Nuclear Factor Kappa B Ligand (RANKL) in Healthy Pubertal Girls-Relationships with Physical Growth and Classical Bone Turnover Markers. Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society, 75, 63-70.
[37] Bandopadhyay, M., Bulbule, A., Butti, R., Chakraborty, G., Ghorpade, P., Ghosh, P., et al. (2014) Osteopontin as a Therapeutic Target for Cancer. Expert Opinion on Therapeutic Targets, 18, 883-895. [Google Scholar] [CrossRef] [PubMed]
[38] Cheng, C., Zhang, F., Tian, J., Tu, M., Xiong, Y., Luo, W., et al. (2015) Osteopontin Inhibits HIF-2α mRNA Expression in Osteoarthritic Chondrocytes. Experimental and Therapeutic Medicine, 9, 2415-2419. [Google Scholar] [CrossRef] [PubMed]
[39] Gao, S., Zeng, C., Song, Y., Tian, J., Cheng, C., Yang, T., et al. (2015) Effect of Osteopontin on the mRNA Expression of ADAMTS4 and ADAMTS5 in Chondrocytes from Patients with Knee Osteoarthritis. Experimental and Therapeutic Medicine, 9, 1979-1983. [Google Scholar] [CrossRef] [PubMed]
[40] Dong, X., Zheng, Y. and Liu, H.Y. (2013) The Clinical Significance of Serum and Joint Fluid Osteopontin, and Thrombin-Cleaved Osteopontin Levels in Osteoarthritis. Chinese Journal of Internal Medicine, 52, 1023-1027.
[41] Newton, K., Strasser, A., Kayagaki, N. and Dixit, V.M. (2024) Cell Death. Cell, 187, 235-256. [Google Scholar] [CrossRef] [PubMed]
[42] 王涛, 彭吾训, 张飞, 等. NMNAT3调节NAD+水平对兔BMSCs线粒体功能及其抗氧化应激能力影响的研究[J]. 中国修复重建外科杂志, 2020, 34(5): 621-629.
[43] 汪甜, 杨丽, 张荣华. 柚皮苷在促大鼠骨髓间充质干细胞骨向分化过程中对MAPK信号通路的影响[J]. 中国病理生理杂志, 2012, 28(5): 769-776.
[44] Jiang, Y., Luo, W., Wang, B., Wang, X., Gong, P. and Xiong, Y. (2020) Resveratrol Promotes Osteogenesis via Activating SIRT1/FoxO1 Pathway in Osteoporosis Mice. Life Sciences, 246, Article 117422. [Google Scholar] [CrossRef] [PubMed]
[45] Zhao, J., Lin, F., Liang, G., Han, Y., Xu, N., Pan, J., et al. (2022) Exploration of the Molecular Mechanism of Polygonati Rhizoma in the Treatment of Osteoporosis Based on Network Pharmacology and Molecular Docking. Frontiers in Endocrinology, 12, Article ID: 815891. [Google Scholar] [CrossRef] [PubMed]
[46] Zha, L., He, L., Liang, Y., Qin, H., Yu, B., Chang, L., et al. (2018) TNF-α Contributes to Postmenopausal Osteoporosis by Synergistically Promoting Rankl-Induced Osteoclast Formation. Biomedicine & Pharmacotherapy, 102, 369-374. [Google Scholar] [CrossRef] [PubMed]
[47] Yao, H., Yao, Z., Zhang, S., Zhang, W. and Zhou, W. (2018) Upregulation of SIRT1 Inhibits H2O2-Induced Osteoblast Apoptosis via Foxo1/β-Catenin Pathway. Molecular Medicine Reports, 17, 6681-6690. [Google Scholar] [CrossRef] [PubMed]
[48] 容婵, 廖莉娅, 林道建, 等. 柚皮苷对地塞米松诱导的小鼠MC3T3-E1细胞凋亡及线粒体凋亡途径的影响[J]. 临床和实验医学杂志, 2017, 16(5): 417-420.
[49] Li, Y., Su, J., Sun, W., Cai, L. and Deng, Z. (2018) Amp-Activated Protein Kinase Stimulates Osteoblast Differentiation and Mineralization through Autophagy Induction. International Journal of Molecular Medicine, 41, 2535-2544. [Google Scholar] [CrossRef] [PubMed]